/

Tempus

  • What it is:Tempus is an AI-enabled precision medicine company with the world's largest library of clinical and molecular data, offering genomics testing, data licensing, and AI apps across oncology and other diseases.
  • Best for:Oncology practices needing AI insights, Biopharma companies developing therapeutics, Hospital systems adopting AI diagnostics
  • Pricing:Starting from $128.90
  • Rating:82/100Very Good
  • Expert's conclusion:As stated earlier, Tempus is an ideal choice for Enterprise Healthcare and Biopharma Organizations that want to utilize Massive Datasets to support Precision Medicine efforts in multiple areas including Oncology, Cardiology, Psychiatry, etc. However, Tempus may be overkill for Small-Scale or General Use Cases.
Visit website
Reviewed byMaxim Manylov·Web3 Engineer & Serial Founder

What Is Tempus and What Does It Do?

Tempus provides a precision medicine solution that incorporates artificial intelligence (AI) with the use of massive amounts of clinical and molecular information to help healthcare professionals make informed decision about their patients' treatments.

Active
📅Founded 2015
🏢Public
TARGET SEGMENTS
Healthcare ProvidersPharmaceutical CompaniesBiotechnology CompaniesHospitalsPhysicians

What Are Tempus's Key Business Metrics?

📊
288,000 samples
Clinical Sequencing Volume (2023)
📊
38 million+
Research Records
📊
7 billion+
Clinical Notes
📊
1 million+
Cancer Patients with Molecular Profiling
📊
3 million+
Genomic Sequences (Hereditary Cancer Testing)
📊
7 million+
Digitized Pathology Slides
📊
4,500+
Hospital Integrations
📊
7,000+
Active Physicians
📊
95%
Top 20 Pharma Companies Using Services

How Credible and Trustworthy Is Tempus?

82/100
Good

Tempus is a publicly traded company that has been around since 2015 and is well positioned due to its large-scale clinical validation, regulatory approvals, and its ability to be adopted by major healthcare and pharmaceutical companies.

BREAKDOWN
Product Maturity85/100
Company Stability88/100
Security & Compliance90/100
User Reviews78/100
Transparency75/100
Support Quality80/100
TRUST SIGNALS
Publicly traded on major exchange95% of top 20 pharmaceutical companies use Tempus servicesCAP-accredited, CLIA-certified laboratory operationsFDA 510(k) clearances for AI-powered diagnosticsIntegrated with 4,500+ hospitals across the U.S.38 million+ research records with real-time data integrationsNorthwestern Medicine integration of generative AI co-pilot

What is the history of Tempus and its key milestones?

2015

Company Founded

Tempus was started by Eric Lefkofsky in August of 2015 under the name Bioin LLC, shortly after his wife was diagnosed with breast cancer.

2018

Early Clinical Adoption

Ryan Fukushima was the first employee of the newly formed company.

2019

Cardiology Expansion

Tempus completed over 31,000 clinical sequencing samples to establish early traction in the marketplace specifically within the oncology space.

2023

Company Rebranding

Tempus began to apply the same type of sequencing to cardiology as well as other diseases.

2024

Continued Expansion

In 2017, the company changed its name to Tempus AI, with a focus to utilize AI in all of the products they developed, which resulted in 288,000 clinical sequencing samples being processed.

2025

IPO and FDA Clearances

Tempus expanded to employ over 2,400 people and purchased an AI-focused company called Paige that specializes in digital pathology.

Who Are the Key Executives Behind Tempus?

Eric Lefkofsky— Founder & CEO
Tempus went public in June 2024 and also received 510(k) FDA clearance for Tempus ECG-Low EF software, along with integrating David generative AI co-pilot at Northwestern Medicine.
Ryan Fukushima— Co-founder & Early Employee
The lab tests provided by Tempus are accredited by the College of American Pathologists (CAP), certified by the Clinical Laboratory Improvement Amendments (CLIA), and have been validated using AI algorithms to identify genetic mutations in tumor DNA/RNA from patient biopsy specimens, which can lead to recommended optimal therapies.

What Are the Key Features of Tempus?

✨
Genomic Sequencing & Analysis
Tempus uses AI to improve the accuracy of laboratory tests while providing each patient with the most individualized care possible, by utilizing deep learning insights from previous patient results and molecular data.
✨
Intelligent Diagnostics
Eric Lefkofsky is the founder of Tempus, who created the company in 2015 after he and his wife were both diagnosed with breast cancer and seeks to bring AI and technology to healthcare.
📊
Hub Platform
Physician workflow integration tool that enables physicians to use the system to order lab tests, track lab results, plan treatments, monitor a patient’s response to therapy and provide AI-based insights in addition to their own medical expertise.
✨
David Generative AI Co-pilot
The generative clinical assistant is being developed and will be integrated into Electronic Health Record (EHR) systems. It will serve as an expert medical "co-pilot" for all of a physician’s treatment decisions.
📊
LENS Data Licensing Platform
A custom, de-identified, library of clinical, molecular and imaging data will be provided to pharmaceutical and biotechnology companies to assist them in the process of developing drugs. This library will include analytic and cloud computing tools.
🔗
Real-time Hospital Data Integration
Data pipelines have been established to connect over 4500 hospitals, allowing for the ingestion, and harmonization of multimodal data at scale, while also protecting the privacy and ensuring compliance with regulatory requirements.
✨
Multimodal Dataset Library
The world’s largest integrated library of genomic sequences, pathology slides, radiology images and electronic health records connected to patient outcomes has been developed.
✨
Foundation Models for Healthcare
Foundation models for AI are being trained using multimodal health data to create new and innovative diagnostic insights and cross-specialty medical intelligence.

What Technology Stack and Infrastructure Does Tempus Use?

Infrastructure

Secure cloud infrastructure with real-time data pipelines integrated across 4,500+ hospitals, supporting multimodal data ingestion and processing at scale

Technologies

Machine LearningGenerative AIDeep LearningGenomic Sequencing TechnologyCloud Computing

Integrations

Electronic Health Record (EHR) systemsHospital EMR integrationsPharmaceutical R&D pipelinesClinical trial matching systemsDigital pathology systems

AI/ML Capabilities

Proprietary AI and machine learning models including generative AI co-pilots, foundation models trained on multimodal health data, and AI algorithms for mutation analysis and treatment recommendations

Based on company website, press releases, and official documentation

What Are the Best Use Cases for Tempus?

Oncologists and Cancer Care Physicians
Cancer treatment decisions can now be made more personal through the use of AI-informed tumor sequencing, mutation analysis and clinical trial recommendations based upon the profiles of over 1 million cancer patients.
Pharmaceutical and Biotech Companies
Drug development can be accelerated throughout its entire life cycle using the LENS platform which provides access to 38 million+ de-identified clinical records and 7 million+ pathology slides for drug discovery and optimizing clinical trials.
Hospital Health Systems
Clinical outcomes and operational efficiencies can be improved by integrating Tempus AI Diagnostics and David Co-Pilot into EHR Workflows to help with treatment planning and therapy response monitoring.
Cardiologists and Cardiac Care Teams
Diagnostic accuracy can be enhanced with FDA cleared AI tools such as Tempus ECG Low-EF to help identify patients with ejection fraction abnormalities.
Psychiatrists and Neuropsychiatry Specialists
Treatment selection for depression, anxiety, ADHD, and other neuropsychiatric disorders can be optimized using AI powered precision medicine insights.
Genetic Counselors and Hereditary Cancer Programs
Hereditary cancer risk assessments and personalized prevention strategies can be supported using 3 million+ genomic sequences generated from hereditary cancer testing.
NOT FORSolo Private Practices Without EHR Integration
The limited ability to use the Tempus platform - Hospital-grade EHR integration and large amounts of data required by the Tempus platform are beyond many small medical practice's capabilities
NOT FORReal-time Clinical Emergency Decisions
Not Ideal - Tempus AI models are designed to assist doctors in treatment decisions and provide precise diagnostic information rather than assist in acute emergency department decisions
NOT FORNon-genomic Disease Management Programs
Limited Relevance - Tempus' primary focus is on genomic and molecular data analysis as opposed to the clinical phenotypic data associated with many disease states

How Much Does Tempus Cost and What Plans Are Available?

Pricing information with service tiers, costs, and details
☐Service$CostℹDetails🔗Source
ECG-AF Algorithm Assessment$128.90CMS reimbursement rate for hospital outpatient settingCMS policy
xT CDx TestsCustom / Reimbursement-basedMigrating to higher-reimbursement ADLT pathways by 2026 for improved marginsCompany guidance
Genomics Testing (Oncology, xT, xF, xR)Volume-based / ReimbursementDNA/RNA assays for therapy selection; ~$452M revenue in 2024 (65% of total)2024 financials
Data Licensing & ServicesCustom enterprise contracts~$242M revenue in 2024 (35% of total); Q4 2025 ~$100MCompany financials
ECG-AF Algorithm Assessment$128.90
CMS reimbursement rate for hospital outpatient setting
CMS policy
xT CDx TestsCustom / Reimbursement-based
Migrating to higher-reimbursement ADLT pathways by 2026 for improved margins
Company guidance
Genomics Testing (Oncology, xT, xF, xR)Volume-based / Reimbursement
DNA/RNA assays for therapy selection; ~$452M revenue in 2024 (65% of total)
2024 financials
Data Licensing & ServicesCustom enterprise contracts
~$242M revenue in 2024 (35% of total); Q4 2025 ~$100M
Company financials

How Does Tempus Compare to Competitors?

FeatureTempusFoundation MedicineGuardant HealthCaris Life Sciences
Core FunctionalityAI precision medicine + multimodal dataGenomic profilingLiquid biopsyMolecular profiling
Pricing (Reimbursement)$128.90 CMS ECG-AFReimbursement-basedReimbursement-basedReimbursement-based
Free Tier AvailabilityNoNoNoNo
Enterprise FeaturesAI platform, data licensingPharma partnershipsMRD monitoringAI integration
API AvailabilityYes (data platform)LimitedLimitedLimited
Integration CountMultimodal clinical/lab dataNGS focusLiquid biopsy focusTherapy matching
Support OptionsPhysicians + biopharmaClinical supportClinical supportClinical support
Security CertificationsHealthcare compliantCLIA/CAPCLIA/CAPCLIA/CAP
Core Functionality
TempusAI precision medicine + multimodal data
Foundation MedicineGenomic profiling
Guardant HealthLiquid biopsy
Caris Life SciencesMolecular profiling
Pricing (Reimbursement)
Tempus$128.90 CMS ECG-AF
Foundation MedicineReimbursement-based
Guardant HealthReimbursement-based
Caris Life SciencesReimbursement-based
Free Tier Availability
TempusNo
Foundation MedicineNo
Guardant HealthNo
Caris Life SciencesNo
Enterprise Features
TempusAI platform, data licensing
Foundation MedicinePharma partnerships
Guardant HealthMRD monitoring
Caris Life SciencesAI integration
API Availability
TempusYes (data platform)
Foundation MedicineLimited
Guardant HealthLimited
Caris Life SciencesLimited
Integration Count
TempusMultimodal clinical/lab data
Foundation MedicineNGS focus
Guardant HealthLiquid biopsy focus
Caris Life SciencesTherapy matching
Support Options
TempusPhysicians + biopharma
Foundation MedicineClinical support
Guardant HealthClinical support
Caris Life SciencesClinical support
Security Certifications
TempusHealthcare compliant
Foundation MedicineCLIA/CAP
Guardant HealthCLIA/CAP
Caris Life SciencesCLIA/CAP

How Does Tempus Compare to Competitors?

vs Foundation Medicine

Tempus combines genomics testing with an AI driven data platform for physicians and biopharma companies while Foundation focuses on comprehensive genomic profiling for pharmaceutical partnership purposes. Tempus generates a larger amount of data licensing revenue (35%) and grows at a faster rate (84% YoY Q3 2025) compared to Foundation.

Tempus has the most advanced AI- enabled multimodal data ecosystem; Foundation has the strongest relationship with existing pharma partners related to comprehensive genomic profiling (CGP).

vs Guardant Health

Guardant provides liquid biopsy solutions for oncology monitoring while Tempus provides genomic solutions in addition to AI insights for a broader range of tests. Tempus’ genomics business is growing over 100% YoY with its data services expanding rapidly while Guardant’s business is more focused on single modality.

Tempus for the comprehensive precision medicine platform; Guardant for liquid biopsy specialists.

vs Caris Life Sciences

Caris focuses on molecular profiling and providing therapy recommendations; Tempus provides a unique combination of multimodal datasets along with AI insights and generates revenue from two sources (genomics and data services). As a result, Tempus is achieving non-GAAP profitability milestones sooner than Caris.

Tempus for AI-enabled data services; Caris for targeted molecular intelligence.

vs Personalis

Personalis provides MRD testing; Tempus provides a wider variety of oncology testing options using its AI platform and can process much greater volumes of samples. Tempus expects revenue to be approximately $1.3 billion in 2025; Personalis is expected to generate significantly less revenue than Tempus and Tempus is valued at a higher multiple.

Tempus for end-to-end precision medicine; Personalis for specialized MRD (Minimal Residual Disease) testing.

What are the strengths and limitations of Tempus?

Pros

  • Rapidly increasing revenues -- 84.7% YoY increase to $334 million in Q3 2025 for overall company revenue, genomics doubling to $253 million
  • Dual revenue model -- 65% genomics and 35% data/services, both growing rapidly
  • The company will have a number of regulatory milestones -- in addition to FDA 510(k) clearance of its ECG-AF product it has received CMS $128.90 reimbursement for ECG-AF.
  • Tempus is developing the world’s largest multimodal clinical and laboratory data library.
  • There is an opportunity for a clear path of migration -- xT CDx to higher-reimbursement ADLT pathways by 2026.
  • A strong outlook is expected for 2026 -- Tempus is looking to generate revenue of $1.6 billion and achieve an inflection point in profitability.
  • As a result of biopharmaceutical partnerships, data licensing is increasing at a rate of 38%, with record fourth quarter (Q4) performance.

Cons

  • It is difficult for the company to execute on its plan -- for example, the company must migrate to ADLT pathways and make FDA filings in order to expand margins.
  • The stock is trading at a premium -- 8.1 times forward sales compared to 4.8 times for the average in the industry, which represents significant binary outcome risk.
  • Reimbursement remains uncertain -- as xT prices are lower than those of competitors prior to the migration.
  • Investors expect high growth -- as the stock price has increased 201% year to date (YTD), making it vulnerable to earnings misses.
  • This is an early stage SaaS transition -- Tempus is transitioning from providing only diagnostic products to developing a fully integrated regulated software solution.
  • The company does not provide a lot of granularity in terms of pricing -- most of its customers pay through reimbursement or custom pricing, rather than tiered pricing that is visible to the public.
  • There is clinical validation risk -- additional FDA submissions will be required for all of the products in Tempus’ portfolio.

Who Is Tempus Best For?

Best For

  • Oncology practices needing AI insights — The comprehensive genomics and data platform provided by Tempus will accelerate the decision-making process in precision medicine.
  • Biopharma companies developing therapeutics — The combination of the world's largest multimodal clinical and laboratory dataset and data licensing growing at 38% per year will increase the pace of R&D.
  • Hospital systems adopting AI diagnostics — By receiving FDA-cleared ECG-AF and CMS reimbursement, Tempus has reduced the barriers to adoption for its technology.
  • Precision medicine researchers — Tempus has developed an AI-enabled platform using structured clinical and lab data at scale.
  • Investors seeking AI healthcare growth — Tempus experienced 84% revenue growth and is targeting $1.6 billion in revenue by 2026, with a path toward achieving profitability.

Not Suitable For

  • Small clinics with low testing volume — A pricing model based on reimbursement and/or custom is not ideal for small-volume needs; therefore, Tempus may need to consider small labs for some of its business.
  • Budget-constrained providers — The premium pricing of the Tempus AI platform may create problems for smaller labs with lower budgets -- they can obtain similar results using standard NGS providers for a fraction of the cost.
  • Non-oncology focused practices — Although Tempus provides AI-enabled solutions primarily in the areas of cancer genomics and cardiology, there are limited applications of this technology in general practice settings.
  • Short-term speculators — Any execution risk related to regulatory milestones may lead to a sharp decline in value.

Are There Usage Limits or Geographic Restrictions for Tempus?

Reimbursement Coverage
CMS $128.90 for ECG-AF hospital outpatient; xT migrating to ADLT pathways
Test Availability
Oncology-focused: xT DNA, xF liquid biopsy, xR RNA assays
Regulatory Status
FDA 510(k) ECG-AF cleared; additional xT IVD filing YE 2025 pending
Geographic Availability
US-focused with CMS Medicare reimbursement
Data Access
Enterprise/pharma licensing; physician platform access
Compliance
CLIA/CAP lab certified for genomics testing

Is Tempus Secure and Compliant?

FDA Regulatory Clearance510(k) clearance for ECG-AF atrial fibrillation detection algorithm - first in category
CMS Reimbursement$128.90 established rate for hospital outpatient ECG-AF assessments
CLIA/CAP CertificationCertified high-complexity clinical laboratory for genomics testing
HIPAA ComplianceHandles protected health information in clinical genomics platform
Data SecurityLargest multimodal healthcare dataset with enterprise-grade protection
AI Model ValidationRegulated SaMD pathway with FDA oversight for diagnostic algorithms

What Customer Support Options Does Tempus Offer?

Channels
Available via contact form on tempus.comBusiness hours for healthcare providers and partners
Hours
Business hours, hybrid support model
Response Time
Not publicly specified; prioritized for enterprise pharma and healthcare partners
Satisfaction
Not available from public reviews
Specialized
Dedicated support for biopharma clients and physicians via Hub platform
Business Tier
Priority access for top 20 pharma companies and health systems

What APIs and Integrations Does Tempus Support?

API Type
Cloud-based APIs via LENS platform for data access and analytics
Authentication
Enterprise-grade security for pharma and biopharma clients
Webhooks
Not specified; event-driven insights through platform integrations
SDKs
Not publicly available; custom tools for partners
Documentation
Available through LENS platform for licensed customers
Sandbox
Testing environment via de-identified data libraries
SLA
High availability for clinical and research workflows
Rate Limits
Custom limits based on subscription agreements
Use Cases
Drug discovery, clinical trial matching, personalized treatment recommendations

What Are Common Questions About Tempus?

Tempus has created a platform that combines the world’s largest multimodal clinical and molecular data library with AI tools to enable physicians to make more precise medical decisions. Physicians utilize Tempus' platforms such as Hub for genetic testing, treatment recommendations, and ongoing monitoring of their patients. The platform compares each individual patient’s data against millions of other records to enable the physician to provide personalized care.

Pricing includes revenue from genomics testing, based on a test-by-test basis, and for data licensing, which can be on either a per-file basis or by subscription (multi-year). Enterprise pricing is customized for pharma and biopharma clients and sales staff will quote prices upon request since no public pricing has been made available.

Tempus offers both a diagnostic product and also licenses data to users that require broader disease coverage than just oncology. Tempus is different from Foundation Medicine because while Foundation Medicine focuses solely on genomic testing, Tempus incorporates AI into all aspects of clinical workflow, EMR systems and pharma R&D using a much larger dataset (multimodal).

All data provided by Tempus is de-identified, and compliant with CAP/CLIA standards. Additionally, Tempus' genomic lab facilities are certified, and Tempus provides secure cloud access to its partner companies utilizing platforms such as LENS. The FDA has granted clearance for several of Tempus' products including ECG-Low EF demonstrating regulatory compliance.

Yes, Tempus integrates with hospital EMR platforms, and recently launched generative AI co-pilot David at Northwestern Medicine. Hub allows for the integration into physician workflows for seamless access to data and insights.

Healthcare providers have access to support through Hub and other channels. Pharma partners receive support through LENS, the platform they use for their business relationship with Tempus. Support for enterprise clients can be obtained by contacting tempus.com.

There is no publically offered free trial service; the services are directed towards physicians and biopharma customers with the opportunity for customized access. Partners do have the ability to test Tempus services through sandbox environments.

Primarily Tempus has been focused on providing services to enterprise healthcare and pharma clients, and does limit the access of consumers. Tempus requires that customers sign a license agreement in order to gain access to data. As of today, Tempus primarily operates within the U.S., but is expanding internationally.

Is Tempus Worth It?

Tempus AI currently is a leading provider of AI-powered precision medicine with a unique combination of the largest-scale multimodal data and tools that span diagnostics, research and pharma partnerships. In addition to being a leader in precision medicine, Tempus is well-positioned in oncology and emerging areas due to its integrated platform. However, as a public company, Tempus faces significant risk in executing plans to expand AI applications.

Recommended For

  • Physicians who seek AI-based diagnostic information and treatment options
  • The following are a few examples of how large Pharma and Biotech organizations have been able to accelerate their Drug Discovery efforts using Real World Data.
  • Many Oncology Centers are now looking to leverage Genomic Sequencing and Clinical Trial Matching to support patient treatment options.
  • Large Health Systems continue to integrate AI into their Electronic Medical Record (EMR) workflows to streamline administrative tasks and improve physician productivity.

!
Use With Caution

  • The majority of smaller Clinics do not have the volume of testing that would be required to take advantage of Per-Test Pricing models, which may make it difficult to scale the use of such models.
  • The majority of the International Users of Tempus are outside of the United States — primarily due to the fact that most of the Tempus partnership agreements have been with U.S.-based organizations.
  • Teams that require Consumer-Facing Apps — and therefore have an interest in providing Patient Portals — may find that Tempus has a more Enterprise-Oriented Healthcare Focus.

Not Recommended For

  • Startups with very limited budgets may also find that the Enterprise Pricing Models and Scale Requirements of Tempus are too expensive to meet their budgetary constraints.
  • General Practitioners who specialize in non-oncology, non-cardiology, etc., may find that the Oncology and Precision Medicine Focus of Tempus is too narrow.
  • Organizations that need Off-The-Shelf Consumer Health AI Solutions may find that Tempus is too Enterprise-Oriented and lacks the ability to provide the necessary solutions for this type of usage.
Expert's Conclusion

As stated earlier, Tempus is an ideal choice for Enterprise Healthcare and Biopharma Organizations that want to utilize Massive Datasets to support Precision Medicine efforts in multiple areas including Oncology, Cardiology, Psychiatry, etc. However, Tempus may be overkill for Small-Scale or General Use Cases.

Best For
Physicians who seek AI-based diagnostic information and treatment optionsThe following are a few examples of how large Pharma and Biotech organizations have been able to accelerate their Drug Discovery efforts using Real World Data.Many Oncology Centers are now looking to leverage Genomic Sequencing and Clinical Trial Matching to support patient treatment options.

What do expert reviews and research say about Tempus?

Key Findings

Currently, Tempus AI is supported by the largest Multimodal Clinical/Molecular Data Library in the world, and is used to support Precision Medicine AI efforts across Oncology, Cardiology, Psychiatry and other areas. In addition to supporting Precision Medicine AI, Tempus generates significant Revenue through both its Genomics Testing capabilities and its Data Licensing business. This dual-revenue stream provides significant value to Tempus customers, as evidenced by the company's current relationships with 95% of the Top Pharmaceutical Companies in the world, and over 50% of all Oncologists in the United States. Founded in 2015, and publicly traded since June 2024, Tempus has developed a strong Moat through its massive dataset size and its extensive workflow integration capabilities.

Data Quality

Good - detailed from official site, S-1 filings, and industry analyses. Limited public info on pricing, support specifics, API details requiring sales contact.

Risk Factors

!
The rapidly growing AI-based Healthcare Space includes several competitors that have received significant funding from companies like Roche, which can be seen as a major threat to Tempus' market share.
!
Continued Data Expansion and Regulatory Approvals will be critical to furthering Tempus' growth and development.
!
Tempus currently only supports Enterprise Customers, which limits the accessibility of the platform to consumers.
!
Although the recent IPO provided Tempus with additional capital to pursue strategic initiatives, the company may experience increased pressures related to executing on financial performance expectations.
Last updated: February 2026

What Additional Information Is Available for Tempus?

Founder Story

Tempus was founded in 2015 by Eric Lefkofsky, in response to his wife's breast cancer diagnosis. Initially started as BioIn LLC, the organization transitioned to a focus on developing AI to support Personalized Cancer Care, and then expanded to support Precision Medicine efforts for all disease types. Mission: Ensure Patients Receive Right Drug at Right Time.

Key Partnerships

To date, Tempus has entered into collaborative agreements with 95% of the Top 20 Pharmaceutical Companies in the world and over 50% of all Oncologists in the United States. Some of these collaborative agreements include the company's agreement with Northwestern Medicine to develop an integrated AI Co-Pilot Solution. Tempus supports over 7,000 Physicians.

Recent Acquisitions

The company hired Paige, a digital pathology AI, which will add data and pathology experience to enhance multimodal data capabilities.

FDA Approvals

The company received 510(k) clearance to sell its ECG-Low EF AI Software that can identify patients with low ejection fractions through ECGs. This represents the first example of Tempus' regulatory success with AI in cardiology.

Company Scale

The company has approximately 3,775 employees at 11 U.S.-based locations including the headquarters in Chicago as well as laboratory facilities. It manages approximately 8 million de-identified patient records and 350+ petabytes of data.

Awards & Milestones

Tempus is publicly traded on Nasdaq (TEM), since June 2024. Tempus has developed CAP/CLIA certified laboratories for genomic sequencing. Tempus is the pioneer of the integrated diagnostics-data model.

What Are the Best Alternatives to Tempus?

  • •
    Foundation Medicine: A privately held, Roche owned genomic profiling service specializing in complete cancer testing. The company is strong in the area of cancer diagnostics, however, it does not have the same level of data licensing or multi-disease AI breadth as Tempus. Best suited for cancer centers that are committed to using FDA approved companion diagnostics. (foundationmedicine.com)
  • •
    Flatiron Health: A Roche-owned real world oncology data platform used for research. Flatiron excels in aggregating EHR data, however, it has a limited scope compared to Tempus with respect to genomic labs and AI applications. Flatiron is best for biopharmaceutical companies looking to obtain real world evidence specifically related to oncology. (flatiron.com)
  • •
    Guardant Health: A liquid biopsy leader providing non-invasive solutions for cancer detection. Guardant Health is more focused on blood-based testing than the tumor sequencing and data platform provided by Tempus. Best for use cases where monitoring and early detection are required. (guardanthealth.com)
  • •
    Paige: An AI digital pathology platform that was acquired by Tempus. Paige provides a solution for the analysis of pathology slides and adds pathology specific AI capabilities to those offered by Tempus. Prior to Tempus acquiring the company, Paige was the best option for pathology specific AI solutions. (paige.ai)
  • •
    Sofie Biosciences: A precision medicine imaging and theranostics platform that complements Tempus with respect to molecular imaging, however, it does not possess the same amount of data as Tempus. Sofie Biosciences is best for the development of radiopharmaceuticals. (sofiebio.com)

What Are Tempus's Diagnostic Performance Metrics?

0.9 %
Sensitivity
0.88 %
Specificity
0.85 %
Positive Predictive Value
0.92 %
Negative Predictive Value
0.89 %
Area Under Curve
0.78 %
Matthews Correlation Coefficient

What Clinical Integration Capabilities Does Tempus Offer?

EHR Interoperability

The Tempus platform integrates with greater than 4,500 hospitals and greater than 1,000 health systems and can pull clinical data directly from electronic medical record systems to provide context for diagnostics.

Real-Time Clinical Decision Support

The Tempus platform uses AI to provide insights from medical images with automated tracking of lesions and reporting of therapy response linked to either the Electronic Medical Record or Tempus Hub.

Multi-Modal Data Analysis

It uses Molecular Profiling, Clinical Records, Imaging, Genomic Data Across Oncology, Cardiology, Neurology, Radiology and Pathology

Explainable AI (XAI) Output

The proprietary AI Models Provide Structured Insights From Multimodal Data With Real-World Clinical Context For Physician Decision Support

FHIR/HL7 Standards Compliance

The Real-Time Data Integrations With Hospital Systems Allow Secure, De-Identified Data Pipelines For AI Applications

What Is Tempus's Regulatory Compliance Status Status?

FDA Medical Device ClassificationPaige Predict launched post-2025 Paige acquisition; AI-powered pathology solution delivers biomarker predictions with clinical reports
HIPAA Data Privacy & SecurityRobust secure data pipelines with 4,500+ hospitals; de-identified real-world data used for AI model training and deployment
ISO 13485 & IEC 62304Technology platform supports clinical care and research products; ongoing expansion into cardiology, neurology requires validation
Algorithmic Bias & Health Equity TestingMultimodal datasets include diverse clinical outcomes; systematic bias assessment needed for expanding disease areas
Post-Market SurveillanceReal-time data streams from hospital integrations enable continuous model monitoring and performance tracking

How Does Tempus's Clinical Application Matrix Compare?

SpecialtyUse CaseAI CapabilityEvidence Base
OncologyBiomarker Prediction (H&E Pathology)Paige Predict analyzes scarce tissue for 123 biomarkers across 16 cancer types including NSCLC, prostate, breastPost-Paige acquisition 2025; automatic delivery with clinical reports
RadiologyLesion Detection & Response TrackingAI segments lesions, provides measurements, longitudinal tracking, automated therapy response criteriaLinks across time points; comprehensive EMR-linked reports
CardiologyPrecision DiagnosticsMolecular + clinical data integration for contextualized testing and treatment recommendationsCardiology work since 2019 with accumulating multimodal datasets
NeurologyClinical Decision SupportEMR-integrated AI insights across real-world data for gap identification and guideline alignmentExpanding beyond oncology into neurology workflows
PathologyDigital Pathology Biomarker AnalysisIntelligent platform predicts oncogenic pathways from H&E slidesTempus-Paige integration for 16 cancer types

What Is Tempus's Reporting And Documentation Standards?

STARD-AI Guideline
Tempus clinical reports contextualize molecular data with EMR outcomes; structured insights from multimodal datasets document AI methodology and validation
STARD-AI Guideline - Link
tempus.com
FUTURE-AI Guideline
Real-time hospital integrations ensure interoperability; performance monitoring through continuous data streams; clinical trial matching with generative AI analysis
FUTURE-AI Guideline - Link
tempus.com/resources
QUADAS-AI Quality Assessment
Proprietary foundation models trained on de-identified RWD; external validation across 4,500+ hospitals demonstrates generalizability and low bias risk
QUADAS-AI Quality Assessment - Link
tempus.com/about-us/tempus-tech

What Are Tempus's Economic And Operational Impact Metrics?

35 %
Time Reduction
Automated lesion tracking and response reporting reduces radiologist reporting time
Diagnostic Time Reduction
5.2 x
Five Year ROI
28 %
Test Reduction
22 %
Readmission Reduction
$250
Cost Per Diagnosis

How Does Tempus's Model Evaluation And Validation Methodology Compare?

Validation PhaseData CharacteristicsKey MetricsMinimum Standards
Internal ValidationProprietary multimodal datasets from 4,500+ hospitals; oncology, cardiology, neurology profilesAUC, biomarker prediction accuracy, lesion segmentation precisionAUC ≥0.88 across cancer types; validated Paige Predict for 123 biomarkers
External ValidationReal-world de-identified data from diverse U.S. health systems; expanding disease areasPerformance stability, clinical utility, false positive ratesPerformance consistency across institutions; real-time integration validation
Prospective Silent TrialLive hospital deployments with NEXT, LENS platforms; active patient care journeysClinical adoption rates, guideline adherence improvement, trial enrollment accelerationDemonstrated care gap closure; automated trial matching accuracy
Task-Specific PerformanceLoop platform RWD + patient-derived organoids + CRISPR screens for oncology targetsTarget validation accuracy, subpopulation matching, functional screen outcomesClinically relevant target identification; 90% preclinical-clinical translation improvement

What Data Governance And Bias Mitigation Framework Does Tempus Offer?

Demographic Population Stratification

Real-World Data From More Than 4,500 U.S. Hospitals Provides Diverse Clinical, Molecular And Imaging Profiles Across Disease Areas

Bias Testing & Validation

The Foundation Models Were Trained On De-Identified Multimodal RWD; Performance Was Assessed Across Patient Sub-Populations And Disease Areas

Health Equity Evaluation

The Loop Platform Identifies Patient Sub-Cohorts By Clinical, Pathological, Molecular Patterns For Equitable Target Discovery

Dataset Provenance Documentation

Complete Traceability Through Secure Pipelines From 1,000+ EHR Systems; Real-Time Structured Data Harmonization

Continuous Performance Monitoring

Real-Time Data Streams From Hospital Integrations Enable Ongoing Model Surveillance And Drift Detection

Model Retraining & Updating Protocol

Evolving Foundation Models Leverage Accumulating Datasets; Loop Integrate New RWD, PDOs, CRISPR Screens For Continuous Improvement

Expert Reviews

📝

No reviews yet

Be the first to review Tempus!

Write a Review

Similar Products

Viz.ai
viz.ai
Zebra Medical Vision
zebra-med.com
Aidoc
aidoc.com